Heritage Information Systems, Inc.

SmartPA

Clinical Edit Criteria Proposal

Drug/Drug Class: Lyrica® Capsules Clinical Edit
Date: April 23, 2008
Prepared for:
Prepared by: MO HealthNet

☐ **New Criteria** ☒ **Revision of Existing Criteria**

Executive Summary

Purpose: Ensure appropriate utilization and control of Lyrica© (pregabalin).

Why was this Issue Selected: Lyrica® is a branded drug product containing pregabalin. Pregabalin is a GABA analogue with structural similarity and actions similar to gabapentin. It has demonstrated efficacy for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and as adjunctive therapy for adults with partial onset seizures. Lyrica® is the first FDA approved treatment for both of these neuropathic pain states. Lyrica® has linear pharmacokinetics and has been designated as a Schedule V controlled substance. For patients who don't respond to gabapentin, Lyrica® may be a useful alternative.

Program-specific information:

Drug	Dosage	Monthly Cost**
• Lyrica®	*50mg TID*	*$178.20 AWP*
• Gabapentin	*300mg TID*	*$119.66 AWP*

**Monthly cost for treatment of epilepsy, partial seizure in adults

Setting & Population: All patients.

Type of Criteria: ☐ **Increased risk of ADE** ☐ **Non-Preferred Agent**

☒ **Appropriate Indications** ☐

Data Sources:	☐ Only administrative databases	☒ Databases + Prescriber-supplied

Setting & Population

- Drug for review: Lyrica® (pregabalin)
- Age range: All ages
- Gender: Male and female

Approval Criteria

- Appropriate Diagnosis:
  - Therapy will be approved for the following indications:

Condition	Submitted ICD-9 Diagnoses	Inferred Drugs
Peripheral Neuropathy assoc. with diabetes	250.6x 356.9x 357.2x	Yes
Postherpetic Neuralgia	053.12x 053.13x 357.0x	--
Partial Epilepsy	345.4x 345.5x	--
Fibromyalgia	729.1	--

- Compliance on Lyrica therapy.

Denial Criteria

- Failure to meet approval criteria.

References

1. Facts and Comparisons, p.1006 – 1043c. 2005.
2. USPDI, Micromedex, 2005.
3. Pfizer, Inc., AMCP Formulary Submission Dossier - Lyrica®, Parsippany, NJ. 07054. August 2005/2007.